A Study to Learn More About the Long-Term Safety and Effects of Felzartamab Infusions in Adults With Kidney Transplants Who Have Antibody-Mediated Rejection (AMR)

NCT07444489 · clinicaltrials.gov ↗

PHASE3

Phase

ENROLLING_BY_INVITATION

Status

120

Enrollment

INDUSTRY

Sponsor class

Conditions

Antibody-mediated Rejection

Interventions

DRUG: Felzartamab

Sponsor

Biogen